BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...protein degradation and higher BET inhibitor efficacy in mice. Theurillat is group leader at the Institute of Oncology Research...
...Therapeutics Inc., Watertown, Mass. Fulcrum Therapeutics Inc., Cambridge, Mass. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Institute of Oncology Research...
BioCentury | Jun 2, 2016
Distillery Therapeutics

Therapeutics: Tripartite motif-containing 24 (Trim24; TIF1)

...Groner, A. et al. Cancer Cell; published online May 26, 2016 doi:10.1016/j.ccell.2016.04.012 CONTACT: Jean-Philippe Theurillat, Institute of Oncology Research...
BioCentury | May 28, 2015
Distillery Therapeutics

Therapeutics: CUB domain containing protein 1 (CDCP1); epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu)

...Alajati, A. et al. Cell Rep.; published online Apr. 16, 2015 doi:10.1016/j.celrep.2015.03.044 CONTACT: Andrea Alimonti, Institute of Oncology Research...
Items per page:
1 - 4 of 4
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...protein degradation and higher BET inhibitor efficacy in mice. Theurillat is group leader at the Institute of Oncology Research...
...Therapeutics Inc., Watertown, Mass. Fulcrum Therapeutics Inc., Cambridge, Mass. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Institute of Oncology Research...
BioCentury | Jun 2, 2016
Distillery Therapeutics

Therapeutics: Tripartite motif-containing 24 (Trim24; TIF1)

...Groner, A. et al. Cancer Cell; published online May 26, 2016 doi:10.1016/j.ccell.2016.04.012 CONTACT: Jean-Philippe Theurillat, Institute of Oncology Research...
BioCentury | May 28, 2015
Distillery Therapeutics

Therapeutics: CUB domain containing protein 1 (CDCP1); epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu)

...Alajati, A. et al. Cell Rep.; published online Apr. 16, 2015 doi:10.1016/j.celrep.2015.03.044 CONTACT: Andrea Alimonti, Institute of Oncology Research...
Items per page:
1 - 4 of 4